Thailand Elite’s Real Estate Partnership Set to Attract Foreign Investors Keen on Relocating and Owning Property in Thailand
27.5.2021 08:00:00 EEST | Business Wire | Press release
Thailand’s sought-after Thailand Elite Residence Program which saw a sharp spike in applications throughout the Covid-19 pandemic in 2020, is set to be even more attractive to foreign investors following a new partnership with more than 10 leading real estate developers in Thailand as part of its Elite Flexible One (EFO) offering.
According to Mr. Somchai Soongswang, President of Thailand Privilege Card Co., Ltd., the operator of Thailand Elite Card, “This pivotal partnership is expected to boost the property sector in Thailand through creating a multi-faceted return for international investors. The EFO option under the privileged entry visa program is of particular interest for applicants who are keen on investing in property either for residence or as an investment. The investors not only gain a return on their property investment but the inherent business & lifestyle benefits of Thai residence”
Each participating developer has a broad and deep selection of available property projects for foreign investors to choose from. Property purchases valued at the minimum of 10 million baht, will afford the buyer consideration for membership of Elite Flexible One, a five-year privilege entry visa – a similar five-year visa (Elite Easy Access) would normally cost THB 600,000 or approximately USD 19,000. The membership not only offers ease of entry into Thailand along with a wide range of VIP benefits, but also business and lifestyle services and rewards as offered by the developer partners to ensure members get the most out of residing in Thailand.
Thailand’s property market has long been considered stable and attractive, both in the form of rental yields, which can reach 8% in Bangkok, as well as capital gains on property value, with return on investment exceeding 10% per annum. Property analysts have predicted that the luxury housing market will be one of the fastest recovering segments as lockdown restrictions eased, with further market recovery expected to continue upon the resumption of freer international travel.
As condo developers are focused on clearing unsold inventory at pre-launch prices, these ready-to-move-into projects offer impressive value. Thai luxury real estate therefore represents a remarkable investment opportunity. Among the developers participating in the limited two-year scheme are well known names such as Sansiri, Ananda Development, AP (Thailand), Origin Property, Raimon Land and Charn Issara Development. There are over 45 projects available including those located in Bangkok’s upscale residential areas which includes Sukhumvit, Silom, Sathorn, and Asoke.
According to Dominic Volek, Group Head of Private Clients at Henley & Partners, the global concessionaire for Thailand Elite, “Savvy investors are now realizing that diversification is as relevant to lifestyle planning as it is to wealth management. As they reevaluate their priorities and seek alternative options for residence, the Thailand Elite Residence Program is often a top choice as it is a safe, prosperous country with an excellent quality of life.”
Since Henley & Partners became the official global concessionaire, the Thailand Elite Residence Program has expanded considerably and now has over 13,000 members. The first of its kind worldwide, the program is managed by Thailand Privilege Card Co. Ltd and offers applicants privilege entry visas, which include a wide range of VIP benefits. The program provides a multiple-entry visa to qualified applicants, allowing them to visit and reside in Thailand for a period of between five and twenty years, at a one-time cost of between THB 600,000 (approximately USD 19,000) and THB 2.14 million (approximately USD 68,000), depending on the option chosen. Benefits include airport limo services and lounge access, expedited immigration formalities, access to world-class healthcare services, dedicated concierge, and various privileges across hotels, shopping centers, golf courses, and more.
Henley & Partners caters to all clients interested in the program, either in person, via one of its offices globally, or virtually, via its online portal, thailandelite-direct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005032/en/
Contact information
Media
Alina Morais
Head of Public Relations, Southeast Asia
alina.morais@henleyglobal.com
+65 9295 4792
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom